Research ExplorerPublicationsAdjuvant cisplatin-based combination chemotherapy for lymph ...

Adjuvant cisplatin-based combination chemotherapy for lymph node (LN)-positive urothelial carcinoma of the bladder (UCB) after radical cystectomy (RC): a retrospective international study of more than 1500 patients

Standard

Adjuvant cisplatin-based combination chemotherapy for lymph node (LN)-positive urothelial carcinoma of the bladder (UCB) after radical cystectomy (RC): a retrospective international study of more than 1500 patients. / Lucca, Ilaria; Rouprêt, Morgan; Kluth, Luis; Rink, Michael; Tilki, Derya; Fajkovic, Harun; Kassouf, Wassim; Hofbauer, Sebastian L; de Martino, Michela; Karakiewicz, Pierre I; Briganti, Alberto; Trinh, Quoc-Dien; Seitz, Christian; Fritsche, Hans-Martin; Burger, Maximilian; Lotan, Yair; Kramer, Gero; Shariat, Shahrokh F; Klatte, Tobias.

In: BJU INT, Vol. 115, No. 5, 01.05.2015, p. 722-727.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Lucca, I, Rouprêt, M, Kluth, L, Rink, M, Tilki, D, Fajkovic, H, Kassouf, W, Hofbauer, SL, de Martino, M, Karakiewicz, PI, Briganti, A, Trinh, Q-D, Seitz, C, Fritsche, H-M, Burger, M, Lotan, Y, Kramer, G, Shariat, SF & Klatte, T 2015, 'Adjuvant cisplatin-based combination chemotherapy for lymph node (LN)-positive urothelial carcinoma of the bladder (UCB) after radical cystectomy (RC): a retrospective international study of more than 1500 patients', BJU INT, vol. 115, no. 5, pp. 722-727. https://doi.org/10.1111/bju.12829

APA

Lucca, I., Rouprêt, M., Kluth, L., Rink, M., Tilki, D., Fajkovic, H., Kassouf, W., Hofbauer, S. L., de Martino, M., Karakiewicz, P. I., Briganti, A., Trinh, Q-D., Seitz, C., Fritsche, H-M., Burger, M., Lotan, Y., Kramer, G., Shariat, S. F., & Klatte, T. (2015). Adjuvant cisplatin-based combination chemotherapy for lymph node (LN)-positive urothelial carcinoma of the bladder (UCB) after radical cystectomy (RC): a retrospective international study of more than 1500 patients. BJU INT, 115(5), 722-727. https://doi.org/10.1111/bju.12829

Vancouver

Lucca I, Rouprêt M, Kluth L, Rink M, Tilki D, Fajkovic H et al. Adjuvant cisplatin-based combination chemotherapy for lymph node (LN)-positive urothelial carcinoma of the bladder (UCB) after radical cystectomy (RC): a retrospective international study of more than 1500 patients. BJU INT. 2015 May 1;115(5):722-727. https://doi.org/10.1111/bju.12829

Bibtex

@article{7d614eb68cc84afda55110b60dff9c65,
title = "Adjuvant cisplatin-based combination chemotherapy for lymph node (LN)-positive urothelial carcinoma of the bladder (UCB) after radical cystectomy (RC): a retrospective international study of more than 1500 patients",
abstract = "OBJECTIVE: To compare outcomes of patients with lymph node-positive urothelial carcinoma of the bladder (UCB) treated with or without adjuvant cisplatin-based combination chemotherapy (AC) after radical cystectomy (RC).PATIENTS AND METHODS: We retrospectively analyzed 1,523 patients with lymph node-positive UCB, who underwent RC with bilateral pelvic lymph node dissection. All patients had no evidence of disease after RC. AC was administered within 3 months. Competing-risks models were applied to compare UCB-related mortality.RESULTS: Of the 1523 patients, 874 (57.4%) received AC. The cumulative 1-, 2- and 5-year UCB-related mortality rates for all patients were 16%, 36% and 56%, respectively. Administration of AC was associated with an 18% relative reduction in the risk of UCB-related death (SHR 0.82, p=0.005). The absolute reduction in mortality was 3.5% at 5 years. The positive effect of AC was detectable in patients ≤70 years, in women, in pT3-4 disease, and in those with a higher lymph node density and lymphovascular invasion. This study is limited by its retrospective and non-randomized design, selection bias, the absence of central pathologic review and lack in standardization of lymph node dissection and cisplatin-based protocols.CONCLUSION: AC seems to reduce UCB-related mortality in patients with lymph node-positive UBC after RC. Younger patients, women and those with high-risk features such as pT3-4 disease, a higher lymph node density and lymphovascular invasion appear to benefit most. Appropriately powered prospective randomized trials are necessary to confirm these findings.",
author = "Ilaria Lucca and Morgan Roupr{\^e}t and Luis Kluth and Michael Rink and Derya Tilki and Harun Fajkovic and Wassim Kassouf and Hofbauer, {Sebastian L} and {de Martino}, Michela and Karakiewicz, {Pierre I} and Alberto Briganti and Quoc-Dien Trinh and Christian Seitz and Hans-Martin Fritsche and Maximilian Burger and Yair Lotan and Gero Kramer and Shariat, {Shahrokh F} and Tobias Klatte",
note = "This article is protected by copyright. All rights reserved.",
year = "2015",
month = may,
day = "1",
doi = "10.1111/bju.12829",
language = "English",
volume = "115",
pages = "722--727",
journal = "BJU INT",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "5",

}

RIS

TY - JOUR

T1 - Adjuvant cisplatin-based combination chemotherapy for lymph node (LN)-positive urothelial carcinoma of the bladder (UCB) after radical cystectomy (RC): a retrospective international study of more than 1500 patients

AU - Lucca, Ilaria

AU - Rouprêt, Morgan

AU - Kluth, Luis

AU - Rink, Michael

AU - Tilki, Derya

AU - Fajkovic, Harun

AU - Kassouf, Wassim

AU - Hofbauer, Sebastian L

AU - de Martino, Michela

AU - Karakiewicz, Pierre I

AU - Briganti, Alberto

AU - Trinh, Quoc-Dien

AU - Seitz, Christian

AU - Fritsche, Hans-Martin

AU - Burger, Maximilian

AU - Lotan, Yair

AU - Kramer, Gero

AU - Shariat, Shahrokh F

AU - Klatte, Tobias

N1 - This article is protected by copyright. All rights reserved.

PY - 2015/5/1

Y1 - 2015/5/1

N2 - OBJECTIVE: To compare outcomes of patients with lymph node-positive urothelial carcinoma of the bladder (UCB) treated with or without adjuvant cisplatin-based combination chemotherapy (AC) after radical cystectomy (RC).PATIENTS AND METHODS: We retrospectively analyzed 1,523 patients with lymph node-positive UCB, who underwent RC with bilateral pelvic lymph node dissection. All patients had no evidence of disease after RC. AC was administered within 3 months. Competing-risks models were applied to compare UCB-related mortality.RESULTS: Of the 1523 patients, 874 (57.4%) received AC. The cumulative 1-, 2- and 5-year UCB-related mortality rates for all patients were 16%, 36% and 56%, respectively. Administration of AC was associated with an 18% relative reduction in the risk of UCB-related death (SHR 0.82, p=0.005). The absolute reduction in mortality was 3.5% at 5 years. The positive effect of AC was detectable in patients ≤70 years, in women, in pT3-4 disease, and in those with a higher lymph node density and lymphovascular invasion. This study is limited by its retrospective and non-randomized design, selection bias, the absence of central pathologic review and lack in standardization of lymph node dissection and cisplatin-based protocols.CONCLUSION: AC seems to reduce UCB-related mortality in patients with lymph node-positive UBC after RC. Younger patients, women and those with high-risk features such as pT3-4 disease, a higher lymph node density and lymphovascular invasion appear to benefit most. Appropriately powered prospective randomized trials are necessary to confirm these findings.

AB - OBJECTIVE: To compare outcomes of patients with lymph node-positive urothelial carcinoma of the bladder (UCB) treated with or without adjuvant cisplatin-based combination chemotherapy (AC) after radical cystectomy (RC).PATIENTS AND METHODS: We retrospectively analyzed 1,523 patients with lymph node-positive UCB, who underwent RC with bilateral pelvic lymph node dissection. All patients had no evidence of disease after RC. AC was administered within 3 months. Competing-risks models were applied to compare UCB-related mortality.RESULTS: Of the 1523 patients, 874 (57.4%) received AC. The cumulative 1-, 2- and 5-year UCB-related mortality rates for all patients were 16%, 36% and 56%, respectively. Administration of AC was associated with an 18% relative reduction in the risk of UCB-related death (SHR 0.82, p=0.005). The absolute reduction in mortality was 3.5% at 5 years. The positive effect of AC was detectable in patients ≤70 years, in women, in pT3-4 disease, and in those with a higher lymph node density and lymphovascular invasion. This study is limited by its retrospective and non-randomized design, selection bias, the absence of central pathologic review and lack in standardization of lymph node dissection and cisplatin-based protocols.CONCLUSION: AC seems to reduce UCB-related mortality in patients with lymph node-positive UBC after RC. Younger patients, women and those with high-risk features such as pT3-4 disease, a higher lymph node density and lymphovascular invasion appear to benefit most. Appropriately powered prospective randomized trials are necessary to confirm these findings.

U2 - 10.1111/bju.12829

DO - 10.1111/bju.12829

M3 - SCORING: Journal article

C2 - 24905084

VL - 115

SP - 722

EP - 727

JO - BJU INT

JF - BJU INT

SN - 1464-4096

IS - 5

ER -